|
|||||
|
|
Low IL-23 levels in peripheral blood and bone marrow at diagnosis of acute leukemia in children increased with the elimination of leukemic burden |
|
| Authors: | Archontis Zampogiannis Christina Piperi Margarita Baka Iliana Zoi Athanasios G Papavassiliou Maria Moschovi |
| Affiliation: | 1. Pediatric Hematology-Oncology Unit, Medical School, "Agia Sophia" Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece;2. Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Contribution: Writing - original draft (equal), Writing - review & editing (equal);3. Department of Pediatric Hematology-Oncology, "P&A Kyriakou" Children's Hospital, Athens, Greece Contribution: Resources (equal), Validation (equal);4. Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece Contribution: Formal analysis (equal), Methodology (equal);5. Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece;6. Pediatric Hematology-Oncology Unit, Medical School, "Agia Sophia" Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece Contribution: Conceptualization (equal), Data curation (equal), Funding acquisition (equal), Project administration (equal), Resources (equal), Supervision (equal), Validation (equal), Visualization (equal), Writing - review & editing (equal) |
| Abstract: | IL-23 is an IL-12 cytokine family member with pleiotropic functions that regulates tumour growth in various cancer types, exhibiting both anti-tumorigenic and pro-tumorigenic properties. Preclinical studies have shown a potential anti-leukemic action on childhood B-ALL cells. The study involved 65 children with acute leukemia 59 patients with acute lymphoblastic leukemia (ALL) and 6 patients with acute myeloid leukemia (AML)] and 27 healthy controls. Using an enzyme-linked immunosorbent assay, we aimed to determine the IL-23 levels in the peripheral blood (PB) and bone marrow (BM) of patients at diagnosis and at the end of the induction therapy (EIT). PB IL-23 levels were lower in leukemia patients compared to the healthy controls. In all acute leukemia patients, IL-23 levels were significantly lower at diagnosis both in PB (P = .015) and in BM (P = .037) compared to the PB and BM concentrations at the EIT. The same pattern was present in both subgroups of ALL and AML patients. The high leukemic burden at diagnosis was related with lower IL-23 levels, which were increased with the disease remission. Considering the anti-leukemic potential of this cytokine, the elevation of the IL-23 concentration at the disease remission indicates a beneficial role of IL-23 in paediatric acute leukemia. |
| Keywords: | acute leukemia acute lymphoblastic leukemia acute myeloid leukemia children IL-23 |
